# Brilinta Taiwan Post Approval Safety Study

> **NCT02406248** · PHASE4 · COMPLETED · sponsor: **AstraZeneca** · enrollment: 108 (actual)

## Conditions studied

- Non ST-elevation Myocardial Infarction

## Interventions

- **DRUG:** Ticagrelor 180mg loading dose taken orally, followed by 90mg twice daily (bd)

## Key facts

- **NCT ID:** NCT02406248
- **Lead sponsor:** AstraZeneca
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-04-23
- **Primary completion:** 2017-02-09
- **Final completion:** 2017-02-09
- **Target enrollment:** 108 (ACTUAL)
- **Last updated:** 2018-10-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02406248

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02406248, "Brilinta Taiwan Post Approval Safety Study". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT02406248. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*